JP2018506966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506966A5 JP2018506966A5 JP2017536549A JP2017536549A JP2018506966A5 JP 2018506966 A5 JP2018506966 A5 JP 2018506966A5 JP 2017536549 A JP2017536549 A JP 2017536549A JP 2017536549 A JP2017536549 A JP 2017536549A JP 2018506966 A5 JP2018506966 A5 JP 2018506966A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- ebov
- acid sequence
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 130
- 241001115402 Ebolavirus Species 0.000 claims description 96
- 239000000427 antigen Substances 0.000 claims description 74
- 108091007433 antigens Proteins 0.000 claims description 74
- 102000036639 antigens Human genes 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 74
- 239000008194 pharmaceutical composition Substances 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 230000008685 targeting Effects 0.000 claims description 12
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 230000005593 dissociations Effects 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 108020000999 Viral RNA Proteins 0.000 claims description 6
- WXJFKKQWPMNTIM-VWLOTQADSA-N [(2s)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid Chemical compound CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O WXJFKKQWPMNTIM-VWLOTQADSA-N 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 4
- 108700012234 Ebola virus VP24 Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 241001115400 Zaire ebolavirus Species 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 208000005156 Dehydration Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 101150010086 VP24 gene Proteins 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 229950008454 favipiravir Drugs 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims description 2
- 238000011277 treatment modality Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000007501 viral attachment Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020081768A JP7672200B2 (ja) | 2015-01-26 | 2020-05-07 | エボラウイルス糖タンパク質に対するヒト抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107581P | 2015-01-26 | 2015-01-26 | |
| US62/107,581 | 2015-01-26 | ||
| US201562161356P | 2015-05-14 | 2015-05-14 | |
| US62/161,356 | 2015-05-14 | ||
| US201562245703P | 2015-10-23 | 2015-10-23 | |
| US62/245,703 | 2015-10-23 | ||
| PCT/US2016/014720 WO2016123019A1 (en) | 2015-01-26 | 2016-01-25 | Human antibodies to ebola virus glycoprotein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081768A Division JP7672200B2 (ja) | 2015-01-26 | 2020-05-07 | エボラウイルス糖タンパク質に対するヒト抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506966A JP2018506966A (ja) | 2018-03-15 |
| JP2018506966A5 true JP2018506966A5 (enExample) | 2019-02-28 |
| JP6829199B2 JP6829199B2 (ja) | 2021-02-10 |
Family
ID=55300806
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536549A Active JP6829199B2 (ja) | 2015-01-26 | 2016-01-25 | エボラウイルス糖タンパク質に対するヒト抗体 |
| JP2020081768A Active JP7672200B2 (ja) | 2015-01-26 | 2020-05-07 | エボラウイルス糖タンパク質に対するヒト抗体 |
| JP2023034449A Pending JP2023065648A (ja) | 2015-01-26 | 2023-03-07 | エボラウイルス糖タンパク質に対するヒト抗体 |
| JP2025019929A Pending JP2025065427A (ja) | 2015-01-26 | 2025-02-10 | エボラウイルス糖タンパク質に対するヒト抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081768A Active JP7672200B2 (ja) | 2015-01-26 | 2020-05-07 | エボラウイルス糖タンパク質に対するヒト抗体 |
| JP2023034449A Pending JP2023065648A (ja) | 2015-01-26 | 2023-03-07 | エボラウイルス糖タンパク質に対するヒト抗体 |
| JP2025019929A Pending JP2025065427A (ja) | 2015-01-26 | 2025-02-10 | エボラウイルス糖タンパク質に対するヒト抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US9771414B2 (enExample) |
| EP (2) | EP3250591B1 (enExample) |
| JP (4) | JP6829199B2 (enExample) |
| KR (1) | KR102641731B1 (enExample) |
| CN (2) | CN107667115B (enExample) |
| AU (2) | AU2016211783B2 (enExample) |
| BR (1) | BR112017015845A2 (enExample) |
| CA (1) | CA2974899A1 (enExample) |
| CL (3) | CL2017001920A1 (enExample) |
| CO (1) | CO2017007619A2 (enExample) |
| EA (1) | EA038993B1 (enExample) |
| IL (1) | IL253358B (enExample) |
| MA (1) | MA41421A (enExample) |
| MX (2) | MX392533B (enExample) |
| MY (4) | MY208081A (enExample) |
| PH (1) | PH12017501277B1 (enExample) |
| PT (1) | PT3250591T (enExample) |
| SG (2) | SG11201705681YA (enExample) |
| TW (1) | TWI710573B (enExample) |
| UY (1) | UY36538A (enExample) |
| WO (1) | WO2016123019A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| WO2017143236A1 (en) | 2016-02-19 | 2017-08-24 | Yoshihiro Kawaoka | Improved influenza b virus replication for vaccine development |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| WO2018017964A2 (en) | 2016-07-21 | 2018-01-25 | Emory University | Ebola virus antibodies and binding agents derived therefrom |
| KR102369014B1 (ko) | 2016-08-16 | 2022-03-02 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| ES3032778T3 (en) | 2016-10-25 | 2025-07-24 | Regeneron Pharma | Methods for chromatography data analysis |
| CN108570106B (zh) * | 2017-03-10 | 2021-07-16 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
| MX2020000228A (es) | 2017-07-06 | 2020-08-10 | Regeneron Pharma | Proceso de cultivo celular para producir una glicoproteina. |
| WO2019139648A2 (en) * | 2017-09-15 | 2019-07-18 | David Weiner | Dna antibody constructs for use against ebola virus |
| MY203415A (en) | 2017-09-19 | 2024-06-27 | Regeneron Pharma | Methods of reducing particle formation and compositions formed thereby |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| RU2686630C1 (ru) * | 2017-12-22 | 2019-04-29 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire) |
| JP7321159B2 (ja) | 2017-12-22 | 2023-08-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 薬剤生成物不純物を特性決定するためのシステム及び方法 |
| US11976109B2 (en) | 2018-01-02 | 2024-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| US20210047388A1 (en) * | 2018-01-31 | 2021-02-18 | The Wistar Institute Of Anatomy And Biology | Nucleic acid antibody constructs for use against ebola virus |
| BR112020013336A2 (pt) | 2018-01-31 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário. |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
| CN108373500A (zh) * | 2018-03-12 | 2018-08-07 | 中国科学院微生物研究所 | 一种热稳定性埃博拉治疗性抗体的制备及应用 |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| DK3768709T3 (da) | 2018-03-19 | 2024-01-29 | Regeneron Pharma | Mikrochip-kapillærelektroforese-assays og reagenser |
| MX2020009851A (es) * | 2018-03-26 | 2020-11-09 | Regeneron Pharma | Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos. |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| TW202448568A (zh) | 2018-07-02 | 2024-12-16 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| WO2020014443A1 (en) * | 2018-07-12 | 2020-01-16 | Vanderbilt University | Pan-ebolavirus neutralizing human antibodies and methods of use therefor |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| BR112020026348A2 (pt) | 2018-08-30 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica |
| CN111138527B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
| CN111138526B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用 |
| CN111138528B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8 |
| CN111138531B (zh) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用 |
| FI3857237T3 (fi) | 2019-01-16 | 2023-05-03 | Regeneron Pharma | Disulfidisidosten luonnehtimismenetelmiä |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| US20200363400A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Competitive Ligand Binding Assays |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
| CN119318636A (zh) | 2019-11-25 | 2025-01-17 | 里珍纳龙药品有限公司 | 使用非水性乳液的持续释放调配物 |
| GB201917480D0 (en) * | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
| EP4354145B1 (en) | 2020-01-21 | 2025-09-17 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20220131923A (ko) | 2020-01-24 | 2022-09-29 | 리제너론 파마슈티칼스 인코포레이티드 | 안정한 항체 제형 |
| TWI859420B (zh) | 2020-02-26 | 2024-10-21 | 美商維爾生物科技股份有限公司 | 抗sars-cov-2抗體及使用其之方法 |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| US20220072141A1 (en) * | 2020-07-13 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
| WO2022074630A1 (en) * | 2020-10-09 | 2022-04-14 | Auxilla Pharmaceuticals And Research Llp | Liquid oral suspension of favipiravir |
| CA3191141A1 (en) | 2020-11-25 | 2022-06-02 | Hunter Chen | Sustained release formulations using non-aqueous membrane emulsification |
| WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| TW202241497A (zh) * | 2021-01-05 | 2022-11-01 | 美商伊米若梅有限公司 | 針對SARS-CoV-2棘蛋白之抗體雞尾酒療法 |
| TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
| AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
| BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| CN118139881A (zh) | 2021-09-20 | 2024-06-04 | 瑞泽恩制药公司 | 控制抗体异质性的方法 |
| JP2024540835A (ja) | 2021-10-07 | 2024-11-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ｐＨメーター較正及び補正 |
| IL311245A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | Systems and methods for pH modeling and control |
| CN118176167A (zh) | 2021-10-26 | 2024-06-11 | 瑞泽恩制药公司 | 用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法 |
| WO2023137443A1 (en) | 2022-01-14 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
| EP4655595A1 (en) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024158880A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| WO2024178213A2 (en) | 2023-02-22 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| WO2024229136A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| WO2025096932A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| CN120623329A (zh) * | 2025-01-15 | 2025-09-12 | 中国人民解放军军事科学院军事医学研究院 | 抗埃博拉病毒vp40蛋白的纳米抗体3e07及在病毒检测中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001016183A1 (en) | 1999-08-30 | 2001-03-08 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| EP3572125A3 (en) | 2008-02-01 | 2019-12-18 | Her Majesty The Queen In Right of Canada as represented by The Minister of Health | Monoclonal antibodies for ebola and marburg viruses |
| EP3351628B1 (en) | 2008-10-24 | 2023-07-26 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Human ebola virus species and compositions and methods thereof |
| PL2438171T3 (pl) | 2009-06-02 | 2015-04-30 | Regeneron Pharma | Komórki z niedoborem fukozylacji |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| WO2011071574A2 (en) | 2009-09-02 | 2011-06-16 | United States Deparment Of The Army, As Represented By The Secretary Of The Army | Monoclonal antibodies against glycoprotein of ebola sudan boniface virus |
| US9346875B2 (en) | 2013-06-03 | 2016-05-24 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
| KR20170047192A (ko) | 2014-02-19 | 2017-05-04 | 조디 베리 | 에볼라 단클론성 항체 |
| CN103864904B (zh) * | 2014-03-04 | 2016-01-20 | 中国人民解放军军事医学科学院生物工程研究所 | 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用 |
| US20170158753A1 (en) | 2014-06-25 | 2017-06-08 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
| US10435461B2 (en) | 2014-08-20 | 2019-10-08 | Albert Einstein College Of Medicine | Therapy for filovirus infection |
| WO2016054598A2 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| WO2016061504A2 (en) | 2014-10-17 | 2016-04-21 | The University Of Chicago | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
-
2016
- 2016-01-22 TW TW105101967A patent/TWI710573B/zh active
- 2016-01-24 MA MA041421A patent/MA41421A/fr unknown
- 2016-01-25 MY MYPI2023001378A patent/MY208081A/en unknown
- 2016-01-25 US US15/005,334 patent/US9771414B2/en active Active
- 2016-01-25 CN CN201680018389.XA patent/CN107667115B/zh active Active
- 2016-01-25 EA EA201791675A patent/EA038993B1/ru unknown
- 2016-01-25 AU AU2016211783A patent/AU2016211783B2/en active Active
- 2016-01-25 PT PT167030303T patent/PT3250591T/pt unknown
- 2016-01-25 EP EP16703030.3A patent/EP3250591B1/en active Active
- 2016-01-25 PH PH1/2017/501277A patent/PH12017501277B1/en unknown
- 2016-01-25 CN CN202110499070.6A patent/CN113354732B/zh active Active
- 2016-01-25 JP JP2017536549A patent/JP6829199B2/ja active Active
- 2016-01-25 BR BR112017015845A patent/BR112017015845A2/pt active Search and Examination
- 2016-01-25 EP EP25206939.8A patent/EP4653051A2/en active Pending
- 2016-01-25 KR KR1020177021579A patent/KR102641731B1/ko active Active
- 2016-01-25 MX MX2017009716A patent/MX392533B/es unknown
- 2016-01-25 MY MYPI2019007583A patent/MY189452A/en unknown
- 2016-01-25 SG SG11201705681YA patent/SG11201705681YA/en unknown
- 2016-01-25 CA CA2974899A patent/CA2974899A1/en active Pending
- 2016-01-25 SG SG10202007835QA patent/SG10202007835QA/en unknown
- 2016-01-25 MY MYPI2021007427A patent/MY196224A/en unknown
- 2016-01-25 MY MYPI2017702504A patent/MY180045A/en unknown
- 2016-01-25 WO PCT/US2016/014720 patent/WO2016123019A1/en not_active Ceased
- 2016-01-26 UY UY0001036538A patent/UY36538A/es active IP Right Grant
-
2017
- 2017-07-09 IL IL253358A patent/IL253358B/en unknown
- 2017-07-26 CL CL2017001920A patent/CL2017001920A1/es unknown
- 2017-07-26 MX MX2021015687A patent/MX2021015687A/es unknown
- 2017-07-27 CO CONC2017/0007619A patent/CO2017007619A2/es unknown
- 2017-08-28 US US15/688,474 patent/US10081670B2/en active Active
-
2018
- 2018-08-22 US US16/108,096 patent/US10501526B2/en active Active
-
2019
- 2019-10-24 US US16/663,261 patent/US10829544B2/en active Active
-
2020
- 2020-02-28 CL CL2020000498A patent/CL2020000498A1/es unknown
- 2020-05-07 JP JP2020081768A patent/JP7672200B2/ja active Active
- 2020-09-30 US US17/039,557 patent/US11530255B2/en active Active
-
2021
- 2021-05-05 AU AU2021202839A patent/AU2021202839A1/en not_active Abandoned
-
2022
- 2022-11-09 US US18/053,927 patent/US12152067B2/en active Active
- 2022-12-26 CL CL2022003763A patent/CL2022003763A1/es unknown
-
2023
- 2023-03-07 JP JP2023034449A patent/JP2023065648A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019929A patent/JP2025065427A/ja active Pending